Patients with bone metastasis due to multiple myeloma, breast or prostate cancer, who received zoledronic acid every 12 weeks for two years, did not have increased risk of skeletal-related events…
The Kerry and Simone Vickar Family Foundation has committed $2 million to establish an endowed chair in their name at the Levine Cancer…
Changes in gene activity in the DNA of multiple myeloma cells can lead to the progression of the disease by shutting down the expression of…
Janssen Biotech and Bristol-Myers Squibb will collaborate in a clinical trial program to evaluate the combination of Darzalex (daratumumab) and Opdivo (nivolumab) in multiple myeloma…
Adding the proteasome inhibitor Velcade (bortezomib) to the standard therapy of Revlimid (lenalidomide) and dexamethasone — a triple combo therapy — significantly extends progression-free survival and…
The monoclonal antibody Darxalex (daratumumab) was recently approved by the U.S. Food and Drug Administration (FDA), in combination with either Revlimid (lenalidomide) and dexamethasone, or…
Aduro Biotech recently presented positive preclinical data showing that its monoclonal antibody, BION-1301, may successfully inhibit multiple myeloma tumor growth, survival, and resistance to other…
The results of a new clinical trial suggest that two extension treatments that are frequently added to standard therapy care in patients with multiple…
Patients with advanced multiple myeloma may benefit from bluebird bio’s novel CAR T-cell therapy bb2121, according to data presented at the 28th EORTC-NCI-AACR Molecular…
The European Commission has granted conditional marketing authorization to Ninlaro (ixazomib) capsules in combination with Revlimid (lenalidomide) and Decadron (dexamethasone) for multiple myeloma patients who…